Lantheus wins final FDA approval for BRAVNETSA radiopharmaceutical in GEP-NETs

Lantheus won final FDA clearance for BRAVNETSA (lutetium Lu 177 dotatate) to treat adult somatostatin receptor-positive GEP-NETs.